PTC Therapeutics (CH:P91)
NASDAQ:P91
P91 Analyst Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
P91 Stock 12 Month Forecast
Average Price Target
$78.87
| Highest Price Target$100.52 | Average Price Target$78.87 | Lowest Price Target$66.47 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
CHF60.8→CHF87.55
Buy
―
Initiated
06/10/26
Jefferies
CHF61.61→CHF68.9
Buy
―
Upgraded
05/27/26
Barclays
CHF97.28
Buy
―
Reiterated
05/27/26
Bank of America Securities
―
Buy
―
Reiterated
05/14/26
J.P. Morgan
CHF64.85→CHF72.15
Buy
―
Reiterated
05/11/26
TD Cowen
CHF60.8→CHF72.96
Buy
―
Upgraded
05/08/26
Raymond James
CHF69.71→CHF77.01
Buy
―
Reiterated
05/08/26
Morgan Stanley
CHF74.58→CHF76.2
Buy
―
Reiterated
05/08/26
RBC Capital
CHF65.66→CHF66.47
Hold
―
Reiterated
05/07/26
Cantor Fitzgerald
CHF100.52
Buy
―
Reiterated
04/28/26
Wells Fargo
CHF69.71
Buy
―
Reiterated
04/13/26
Truist Financial
―
Buy
―
Reiterated
02/27/26
William Blair
―
Buy
―
Reiterated
02/20/26
Goldman Sachs
CHF40.53→CHF44.58
Sell
―
Reiterated
12/03/25
Leerink Partners
CHF43.77
Hold
―
Reiterated
10/16/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
CHF60.8→CHF87.55
Buy
―
Initiated
06/10/26
Jefferies
CHF61.61→CHF68.9
Buy
―
Upgraded
05/27/26
Barclays
CHF97.28
Buy
―
Reiterated
05/27/26
Bank of America Securities
―
Buy
―
Reiterated
05/14/26
J.P. Morgan
CHF64.85→CHF72.15
Buy
―
Reiterated
05/11/26
TD Cowen
CHF60.8→CHF72.96
Buy
―
Upgraded
05/08/26
Raymond James
CHF69.71→CHF77.01
Buy
―
Reiterated
05/08/26
Morgan Stanley
CHF74.58→CHF76.2
Buy
―
Reiterated
05/08/26
RBC Capital
CHF65.66→CHF66.47
Hold
―
Reiterated
05/07/26
Cantor Fitzgerald
CHF100.52
Buy
―
Reiterated
04/28/26
Wells Fargo
CHF69.71
Buy
―
Reiterated
04/13/26
Truist Financial
―
Buy
―
Reiterated
02/27/26
William Blair
―
Buy
―
Reiterated
02/20/26
Goldman Sachs
CHF40.53→CHF44.58
Sell
―
Reiterated
12/03/25
Leerink Partners
CHF43.77
Hold
―
Reiterated
10/16/25
Best Analysts Covering PTC Therapeutics
3 Months
Success Rate
14/17 ratings generated profit
Average Return
+16.52%
Copying Tiago Fauth's trades and holding each position for 3 Months would result in 82.35% of your transactions generating a profit, with an average return of +16.52% per trade.
1 Year
Success Rate
17/17 ratings generated profit
Average Return
+55.74%
Copying Tiago Fauth's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +55.74% per trade.
2 Years
Success Rate
17/17 ratings generated profit
Average Return
+99.42%
Copying Tiago Fauth's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +99.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
P91 Analyst Recommendation Trends
Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
3
3
6
6
6
Buy
18
13
11
9
10
Hold
10
10
7
5
4
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
26
24
20
20
Each month's total comprises the sum of three months' worth of ratings.
P91 Financial Forecast
P91 Stock Forecast FAQ
What is CH:P91’s average 12-month price target, according to analysts?
Based on analyst ratings, PTC Therapeutics’s 12-month average price target is 78.87.
What is CH:P91’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:P91, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PTC Therapeutics a Buy, Sell or Hold?
PTC Therapeutics has a consensus rating of Strong Buy, which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
What is PTC Therapeutics’s share price target?
The average share price target for PTC Therapeutics is 78.87. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $100.52 ,and the lowest forecast is $66.47. The average share price target represents N/A Increase from the current price of N/A.
The highest analyst share price target is $100.52 ,and the lowest forecast is $66.47. The average share price target represents N/A Increase from the current price of N/A.
What do analysts say about PTC Therapeutics?
PTC Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of PTC Therapeutics?
To buy shares of CH:P91, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.